Kailera Therapeutics Inc (KLRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | |
| Operating Expenses | 158,340 | 0 |
| Operating Income | -158,340 | N/A |
| Other Income | 9,385 | 0 |
| Pre-tax Income | -148,955 | 0 |
| Net Income Continuous | -148,955 | N/A |
| Net Income | $-148,955 | $N/A |
| EPS Basic Total Ops | -949.00 | N/A |
| EPS Basic Continuous Ops | -948,757.90 | N/A |
| EPS Diluted Total Ops | -949.00 | N/A |
| EPS Diluted Continuous Ops | -948,757.90 | N/A |
| EBITDA(a) | $-158,030 | $N/A |